Merine

Quick links to important sections

Merine

Method of action: Antidepressant, Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merine

Quick Facts

Property Description
Active ingredient Maprotiline (as the Hydrochloride)
Form Film-coated tablet
Pharmacological class Tetracyclic Antidepressant (TeCA)
Common use Mood stabilization and emotional balance
Origin Synthetic drug

What Type of Medicine is Merine?

Merine is a synthetic psychotropic agent classified as a Tetracyclic Antidepressant (TeCA), belonging to the second-generation antidepressant group. This drug is a single-ingredient product defined by its sole active compound, Maprotiline. Pharmacological studies have clinically recognized Maprotiline for its role in regulating specific neural pathways, differentiating it from earlier antidepressant compounds. The general purpose of this medication is to support the brain in regulating mood and emotional stability, typically for adult patients requiring prescription medication.


Merine's Active Ingredient and Physical Form

The therapeutic action of Merine relies exclusively on its active compound, Maprotiline, a complex tetracyclic compound and secondary amine. Its official chemical profile notes that its mechanism involves actions on specific neurotransmitter systems. The standard dosage form is a film-coated tablet intended for oral ingestion, utilizing pharmaceutical excipients to deliver the measured dose. As a single-ingredient product, the predictable effect is solely attributed to Maprotiline, ensuring a defined method of systemic delivery. Popular brands containing this same formulation include Ludiomil, demonstrating its established presence in clinical practice.


How Maprotiline Works at a High Level

Maprotiline's classification is rooted in its mechanism principle as a Non-selective Monoamine Reuptake Inhibitor with a pronounced selectivity for norepinephrine. By preventing the reabsorption (reuptake) of the natural chemical messenger norepinephrine back into nerve cells, Merine increases its availability in the brain's pathways. The general purpose of this action is to help support the nervous system in restoring emotional equilibrium, which manifests as an ability to stabilize mood and alleviate symptoms of persistent emotional dysregulation.

Regulatory References

  1. Antidepressants - StatPearls - NCBI Bookshelf

What side effects are possible with Merine?

Official Adverse Effects and Safety Profile

Regulatory documents define Merine's safety profile based on its classification as a tetracyclic antidepressant. Adverse reactions are grouped by System-Organ Class (SOC) and frequency, derived from clinical and post-marketing data.

Frequency-Classified Common Adverse Reactions

The most frequently documented effects listed in official labeling include Very Common (ge 10%): dry mouth and drowsiness. Common (ge 1% to < 10%) effects include dizziness, tremor, constipation, blurred vision, headache, and fatigue/weakness.

System-Organ Class (SOC) Examples of Officially Listed Adverse Reactions
Nervous System Dizziness, tremor, numbness, tingling, seizures/convulsions.
Psychiatric Disorders Anxiety, agitation, insomnia, confusion, hallucinations.
Gastrointestinal Constipation, nausea, vomiting, paralytic ileus.
Cardiovascular Hypotension, tachycardia, arrhythmia, heart block.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions: Officially documented serious risks include suicidal thoughts and behavior (particularly in those aged 24 and younger, noted in the FDA Boxed Warning), severe cardiac events (e.g., stroke, myocardial infarction, severe arrhythmias), and potentially life-threatening conditions like seizures and severe hematologic (e.g., agranulocytosis) or hepatic disorders.

Population-Specific Safety Notes: Older adults are noted to be more susceptible to side effects such as confusion, dizziness, and anticholinergic effects (e.g., urinary retention). Caution is required for patients with pre-existing cardiovascular disease or those with a history of seizure disorders.

Safety-Related Restrictions: Merine is contraindicated for use in combination with Monoamine Oxidase Inhibitors (MAOIs), during the acute recovery phase following a myocardial infarction, and in cases of severe hepatic impairment.

Time-Related Safety Patterns: The risk of suicidality is emphasized as being elevated during the initial phase of treatment and following dose adjustments. Furthermore, abrupt discontinuation is associated with withdrawal symptoms and is not recommended in regulatory prescribing information.

Overdose and Emergency Response

The regulatory documentation for Merine (Maprotiline) defines the potential for severe, life-threatening outcomes in the event of an overdose, necessitating immediate emergency action. The gravest threats documented involve the Central Nervous System (CNS) and the Cardiovascular System. Manifestations of overdose can include severe drowsiness, motor unrest, muscular twitching, and agitation, but can progress to critical clinical signs such as convulsions (seizures), disturbances of consciousness progressing to deep coma, and respiratory depression. Cardiovascular compromise may present as severe hypotension and critical cardiac arrhythmias, including impaired conduction. These severe outcomes can occur suddenly.

Due to the acute risks, official labeling strictly mandates that individuals seek immediate medical attention and contact a local poison control center or emergency room for any suspected overdosage. All patients must be hospitalized and kept under close surveillance. Overdose in children is specifically noted as requiring prompt hospitalization and continuous observation.

Management of Maprotiline overdosage is required to be strictly symptomatic and supportive. Regulatory documents state that no specific antidote is known for reversing the effects. Therefore, procedural interventions such as establishing and maintaining an adequate airway, along with stomach emptying procedures like gastric lavage, are utilized to stabilize the patient.

Therapeutic Uses of Merine

What Merine Treats: Main Uses and Benefits

Merine is commonly used for the drug treatment of various forms of depressive illness, including Major Depressive Disorder (MDD) and persistent conditions like Depressive Neurosis (Dysthymia). The medication is also considered relevant for the depressed phase of manic-depressive illness. This therapeutic approach is applied across conditions presenting with acute or disruptive episodes, particularly those where symptoms may interfere with functional stability.

The medication is commonly used to help with pronounced emotional symptoms, such as loss of pleasure (anhedonia) and feelings of worthlessness, while also addressing associated issues like anxiety, tension, and insomnia. Merine is relevant in contexts marked by increased discomfort, as it provides support that generally helps ease the overall symptom burden and contributes to emotional stability.

Quick Fact: Relief for Co-occurring Symptoms
Symptom focus Anxiety, tension, and sleep disturbances
Benefit type Contributes to improved comfort during symptomatic periods
Use context Applied during phases of increased distress or discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Merine (Maprotiline)

Official regulatory documents define strict criteria for the use of Merine, determining who is eligible and who is contraindicated.

Populations Who Must Not Use Merine

Merine is contraindicated in several specific populations, meaning use is explicitly prohibited. These include:

  • Patients with a known history of seizures or convulsive disorders.
  • Individuals in the acute recovery phase following a myocardial infarction (MI).
  • Those currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping an MAOI.
  • Patients with narrow-angle glaucoma, urinary retention, or severe impairment of the liver or kidney (hepatic/renal failure).

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Adults (18+ years) Eligible under standard labeled conditions.
Pediatric (<18 years) Not recommended; safety and effectiveness have not been established.
Older Adults (Geriatric) Eligible, but use may be restricted to lower starting doses.
Pregnancy Use is restricted and should be administered only if clearly needed.
Lactation Caution is recommended or avoided, as the medicine is excreted into human milk.

Use also requires caution in patients with a history of cardiac arrhythmias or hyperthyroidism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific substances and drug classes that may alter the effectiveness or safety profile of Merine. These interactions are categorized to ensure safe co-administration.

Interaction Scope Regulatory Statement Basis
Medicinal Product Categories Valproic acid, sodium valproate, or divalproex sodium (anticonvulsant agents).
Specific Interaction-Related Restriction Co-administration may reduce the plasma concentration of valproic acid or related compounds. Regulatory documents warn that this interaction may lead to subtherapeutic levels of the anticonvulsant and loss of seizure control.
High-Level Classification Pharmacokinetic (PK) interaction affecting the co-administered drug, necessitating close monitoring or alternative therapy.
Other Interactions Probenecid competes for active tubular secretion in the kidney. Co-administration of Probenecid results in increased plasma concentrations and a prolonged half-life of Merine.

Merine is not reported to significantly affect the pharmacokinetics of many co-administered medicines that undergo metabolism via cytochrome P450 enzymes. Interactions with specific food, alcohol, or herbal products are not typically highlighted in the primary interaction sections of official regulatory labels for this medicine. The official profile primarily focuses on pharmacokinetic changes that necessitate vigilance regarding other medications, such as the described effect on valproate exposure, and the effect of Probenecid on Merine levels.

Mechanism of Action

How Merine Works

The mechanism of action involves interactions with two key biological pathways in the central nervous system.


Potentiation of Noradrenergic Signaling

The core mechanism involves inhibition of the Norepinephrine Transporter (NET). By blocking this transporter, Merine immediately increases the concentration and duration of norepinephrine ( NE) in the synaptic space. This sustained potentiation of NE signaling drives slow neuroadaptive changes in the brain's circuitry, resulting in the modulation of central neural signaling.


Modulation of Central Arousal Receptors

Merine acts as an antagonist at the central Histamine H1 Receptors ( H1 R). This action directly interferes with histamine-mediated arousal pathways. The resultant dampening of histaminergic signaling produces a change in central arousal state. This effect co-occurs with the mechanism on the noradrenergic system.

Dosage and Administration Information

The use of Merine, which contains the active ingredient Maprotiline, is structured around specific dosage rules and administration patterns. The medicine is formulated as a film-coated tablet for oral administration, available in strengths of 25 mg, 50 mg, and 75 mg.

For most outpatients, treatment typically begins with an initial daily dose of 75 mg, which may be administered once daily or in divided doses. The total dosage during maintenance should generally not exceed 150 mg daily, though the absolute maximum recommended dose is 225 mg per day.

Frequency and Dosage Adjustment

The administration schedule requires careful initial management. The starting dose is maintained for a period of at least two weeks to allow for stabilization before any increase is considered. Subsequent adjustments, when necessary, should be gradual, typically using increments of 25 mg. When administered once daily, the dose is generally taken at bedtime. Merine may be taken with or without food.

Specific procedural guidance exists for certain populations: older adults require a substantially lower regimen, starting at 25 mg daily, with maintenance doses usually between 50 mg and 75 mg per day. Furthermore, if a patient misses a scheduled bedtime dose, guidelines indicate that the missed amount should not be taken the following morning, and the 75 mg tablets should not be halved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Merine (Maprotiline)

This section provides an objective overview of the clinical research conducted on Merine (maprotiline), detailing the types of studies that have been conducted and the evidence patterns they describe. Findings presented here reflect group patterns observed in studies and are intended only to provide context on the available evidence, not individual predictions or clinical guidance.


Evidence for Use in Major Depressive Disorder (MDD)

The core evidence base for Merine, which was studied for Major Depressive Disorder (MDD), consists primarily of older Randomized Controlled Trials (RCTs) and comparative studies. These trials were used in research exploring how symptoms change over time in adult populations, including both hospitalized and outpatient settings. Short-term reports describe patterns observed related to changes in symptom scores over periods typically lasting only a few weeks. Some findings describe group patterns observed in which a number of subjects met specific criteria for a measured outcome during the observation period.


Evidence for Use in Persistent Depressive Conditions

Merine was studied for use in conditions characterized by fluctuating or episodic manifestations, including Depressive Neurosis (Dysthymia), and research also explored its application during the Depressed Phase of Manic-Depressive Illness. This evidence base includes comparative trials and observational data. The quantity of controlled research specifically focused on the depressed phase in the context of bipolar disorder is limited compared to the evidence base for MDD.


Research on Associated Symptoms

Merine was evaluated in studies where symptoms like anxiety, tension, and sleep disturbances were measured as secondary endpoints. This evidence provides context for short-term changes in associated symptoms, with some reports detailing specific changes in measurements related to sleep patterns and generalized tension.


What Remains Uncertain in the Research Landscape

The majority of the controlled clinical evaluation research is limited to the short-term treatment of acute symptoms, with follow-up durations typically ranging from 3 to 12 weeks. Key questions regarding the durability of an observed change or studies exploring the compound for maintenance therapy and relapse prevention are not fully established by high-certainty, long-term controlled data. Furthermore, subgroup findings are uncertain for many specialized populations, meaning the results apply only to the populations studied and research is ongoing to better characterize long-term and specialized outcomes.

Key Studies & References

  1. Antidepressant Treatment of Depression in the Elderly: Efficacy and Safety Considerations

Frequently Asked Questions (FAQ)

Common questions about Merine (FAQ)


Q: How long does Merine usually take to start working?

Official instructions advise that it may take a few weeks or longer for a person to feel the full intended benefit of the active ingredient, Maprotiline. The starting dose is generally maintained for a period of at least two weeks to allow for initial stabilization.


Q: Is Merine used for pain relief or something else entirely?

Merine is prescribed for the management of conditions such as depression, anxiety associated with depression, and the depressed phase of bipolar disorder. Regulatory documents define its use around supporting mood and emotional balance. It is not listed as having an official indication for pain relief.


Q: Can Merine affect my sleep pattern?

Yes, official labeling indicates that Merine can affect sleep patterns in different ways. Drowsiness is listed as a very common side effect, which may cause sedation. However, insomnia (difficulty sleeping) is also listed as a less frequent adverse reaction.


Q: What happens if I stop taking Merine suddenly?

Discontinuing the medication abruptly may be associated with withdrawal symptoms, sometimes referred to as Antidepressant Discontinuation Syndrome. These reported effects can include dizziness, headache, irritability, sleep problems, and a general feeling of being unwell. Official guidance emphasizes that patients should not stop taking the medicine suddenly.


Q: Is it necessary to take Merine at the exact same time every day?

Patient instructions generally advise taking Merine at around the same time every day to maintain a consistent level of the medicine in the body. If the medicine is prescribed as a once-daily dose, it is generally advised to take it at bedtime.


Q: Does Merine have a risk of addiction or dependence?

Merine is not classified as a controlled drug by regulatory agencies. While generally considered to have a low risk of abuse, physical dependence can develop. For this reason, the abrupt cessation of the medication, particularly after long-term use, is associated with a risk of withdrawal symptoms.


Q: Why do official documents refer to Merine using a different scientific name?

Merine is the brand name of the drug. Official regulatory documents and scientific literature typically use the name of the active ingredient, which is Maprotiline (or Maprotiline Hydrochloride). This is standard practice to clearly identify the chemical compound regardless of its market name.


Q: Can men and women expect different side effects from Merine?

While many side effects are common to both sexes, official labeling lists potential sexual dysfunction, with specific manifestations for men and women. Official information indicates that the presentation of adverse effects may vary, and a prescribing professional can provide context.


Q: What kind of research has been done on Merine?

The evidence base consists primarily of older Randomized Controlled Trials (RCTs), comparative studies, and observational data. This research focused on the drug's use in Major Depressive Disorder and conditions characterized by fluctuating or episodic emotional manifestations.


Q: How is Merine described in official drug information leaflets?

The manufacturer provides a patient information sheet (Medication Guide) with the medicine. This guide summarizes essential safety details, including information about antidepressant risks, depression, and warnings concerning suicidal thoughts or actions, as required by regulatory agencies.


Q: Does Merine affect my ability to drive or operate machinery?

Because this medication may cause drowsiness (a very common effect), Official guidance suggests that individuals should wait until they are certain how the medication affects their mental alertness and coordination before driving or operating machinery.


Q: What is the risk of a serious allergic reaction to Merine?

Merine is strictly contraindicated (prohibited) for use in patients with known hypersensitivity (a severe allergy) to the drug. Reported signs of a severe allergic reaction can include difficulty breathing, hives, and swelling of the mouth, tongue, or face.


Q: Are the reported side effects of Merine generally mild or severe?

The official profile lists both common effects and serious risks. Common effects, such as dry mouth and drowsiness, are often considered mild. However, the medication also carries warnings for serious adverse risks, including seizures, severe cardiac events, and suicidal thoughts or behavior.


Q: Is there a generic version of Merine available?

In the United States, the specific brand formulation containing Maprotiline has been discontinued. The availability of a generic version of Maprotiline can vary significantly depending on the country and its current market status.


Q: How often do people typically need to take Merine?

Official patient instructions indicate that Merine tablets are usually taken once to three times a day. The specific frequency is determined by the prescribing professional based on the treatment plan.


Q: Are there different forms of Merine (e.g., tablet, liquid)?

According to official documentation, the standard formulation of Merine (Maprotiline) is a film-coated tablet intended for oral administration. It is supplied in specific strengths, such as 25 mg, 50 mg, and 75 mg.


Q: Does Merine interact with any common blood pressure medications?

Regulatory information notes that Maprotiline may have additive effects in lowering blood pressure when co-administered with certain other medications. This includes specific diuretics and certain hypertension drugs, which may necessitate close professional monitoring.


Q: What percentage of patients experience significant side effects with Merine?

Official labeling lists side effects using descriptive frequency ranges rather than a single overall percentage. For instance, Very Common side effects occur in ge 10% of patients, and Common effects occur in ge 1% to < 10%.


Q: Is Merine available without a prescription anywhere in the world?

Maprotiline is strictly designated as a prescription-only medication in all major regulatory jurisdictions, including the United States, Australia, and Brazil. It is not available over the counter.


Q: Does Merine affect the results of any common medical tests?

Maprotiline has been reported to cause an increase in serum glucose (blood sugar) and a decrease in glucose tolerance. Professional monitoring may be required for individuals with conditions like diabetes.


Q: If I already take a prescription for depression, can I also take Merine?

Merine is strictly contraindicated (prohibited) for use at the same time as, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI). This is a specific class of antidepressant medication.


Q: Does Merine cause weight gain or weight loss?

Official information lists both increased appetite and weight gain and weight loss as less common adverse effects associated with the drug. Changes in weight may be observed during treatment.


Q: Can Merine cause confusion or memory issues in some patients?

Confusion is listed as a potential adverse reaction, particularly in older adults. As a medication with anticholinergic properties, it may also contribute to cognitive impairment or confusion.


Q: What research evidence exists regarding Merine's use in children or adolescents?

Merine is generally not recommended for use in children and adolescents (under 18 years of age). This is because the safety and effectiveness of the drug have not been definitively established in this specific population.

How should Merine be stored and disposed of?

The official labeling for Merine (Maprotiline hydrochloride) strictly defines its storage and disposal requirements to ensure product quality and safety.

Storage and Handling

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (20 C to 25 C), protecting the tablets from freezing and excessive heat.
Protection Keep the medicine in a closed, tightly sealed container and store it away from direct light and moisture.
Child Safety The product must be stored out of the reach of children.

Disposal Instructions

Outdated or unused Merine must be disposed of safely. The preferred method is a designated drug take-back program. If this is unavailable, the tablets should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a plastic bag, and placed in the household trash. The labeling explicitly instructs not to flush Merine down the toilet or pour it down any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merine found in:

A-Z Index: